Hypoactive sexual desire disorder

被引:3
|
作者
Davison, Sonia L. [1 ]
机构
[1] Monash Univ, Womens Hlth Res Program, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med,Alfred Ctr, Melbourne, Vic 3004, Australia
关键词
female sexual dysfunction; hypoactive sexual desire disorder; women; PREMENOPAUSAL WOMEN EFFICACY; PLACEBO-CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; MENOPAUSAL WOMEN; TESTOSTERONE PATCH; ANDROGEN LEVELS; SAFETY; FLIBANSERIN; THERAPY; DYSFUNCTIONS;
D O I
10.1097/GCO.0b013e328355847e
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review Hypoactive sexual desire disorder (HSDD) is the most prevalent female sexual dysfunction, with estimates of prevalence approximating 10%. By definition it is a deficiency of sexual desire that causes distress. HSDD has no single cause, but physiological, psychological and socio-cultural factors underpinning female sexual desire may all be important in its development. Recent findings Medical therapeutic strategies to date have concentrated on modulation of hormone levels, particularly androgen administration, yet few products have been approved for the treatment of HSDD in developed countries. More recent medical targets have included agents with 5-hydroxytryptamine agonist activity. Psychological therapeutic approaches have been infrequently studied but concentrate on cognitive behavioural therapy. Summary HSDD is an evolving diagnosis, the existence of which has been questioned by some critics. Whilst HSDD remains the subject of ongoing research, its title and definition are under debate as a new edition of the Diagnostic and Statistical Manual of the American Psychiatric Association approaches publication in 2012.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 50 条
  • [31] Etiological factors in female Hypoactive Sexual Desire Disorder
    Hubin, A.
    De Sutter, P.
    Reynaert, C.
    SEXOLOGIES, 2011, 20 (03) : 149 - 157
  • [32] Pharmacologic treatment options for hypoactive sexual desire disorder
    Bolour, Sheila Y.
    Braunstein, Glenn D.
    WOMENS HEALTH, 2005, 1 (02) : 263 - 277
  • [33] The Presentation of Hypoactive Sexual Desire Disorder in Premenopausal Women
    Maserejian, Nancy N.
    Shifren, Jan L.
    Parish, Sharon J.
    Braunstein, Glenn D.
    Gerstenberger, Eric P.
    Rosen, Raymond C.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 (10): : 3439 - 3448
  • [34] Hypoactive sexual desire disorder in women: the role of testosterone
    Marques, S.
    Gomes, F.
    Fernandes, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S217 - S217
  • [36] Characterization of hypoactive sexual desire disorder (HSDD) in men
    DeRogatis, L.
    Rosen, R.
    Goldstein, I
    Werneburg, B.
    Kempthorne-Rawson, J.
    Sand, M.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 422 - 423
  • [37] Cognitive factors in women hypoactive sexual desire disorder
    Geonet, M.
    De Sutter, P.
    Zech, E.
    SEXOLOGIES, 2013, 22 (01) : E9 - E15
  • [38] Flibanserin for hypoactive sexual desire disorder: place in therapy
    Gelman, Faina
    Atrio, Jessica
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2017, 8 (01) : 16 - 25
  • [39] Testosterone Supplementation for Hypoactive Sexual Desire Disorder in Women
    Woodis, C. Brock
    McLendon, Amber N.
    Muzyk, Andrew J.
    PHARMACOTHERAPY, 2012, 32 (01): : 38 - 53
  • [40] Safety of Flibanserin in Men with Hypoactive Sexual Desire Disorder
    Saffati, G.
    Naeem, T.
    La, T. M.
    Kaaki, B.
    Khera, M.
    JOURNAL OF SEXUAL MEDICINE, 2024, 21